Progyny (NASDAQ:PGNY) Given New $19.00 Price Target at Canaccord Genuity Group

Progyny (NASDAQ:PGNY) had its price target lowered by Canaccord Genuity Group from $26.00 to $19.00 in a research report report published on Wednesday,Benzinga reports. The firm currently has a hold rating on the stock.

A number of other analysts have also weighed in on the company. KeyCorp lowered their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a research report on Monday, December 29th. Truist Financial decreased their price objective on Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research note on Wednesday, January 21st. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $28.45.

Progyny Stock Performance

NASDAQ:PGNY opened at $17.52 on Wednesday. Progyny has a one year low of $16.75 and a one year high of $28.75. The firm has a market cap of $1.43 billion, a P/E ratio of 26.95, a P/E/G ratio of 1.20 and a beta of 1.01. The firm has a 50-day simple moving average of $22.63 and a 200-day simple moving average of $22.82.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, research analysts predict that Progyny will post 0.6 EPS for the current fiscal year.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 7,455 shares of company stock worth $129,515 over the last 90 days. Corporate insiders own 9.40% of the company’s stock.

Institutional Trading of Progyny

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its stake in Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares during the last quarter. Teza Capital Management LLC grew its stake in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after acquiring an additional 516 shares during the last quarter. Leibman Financial Services Inc. increased its holdings in shares of Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after acquiring an additional 528 shares in the last quarter. Aristides Capital LLC increased its holdings in shares of Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after acquiring an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP raised its position in shares of Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after purchasing an additional 531 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.